The BCR-ABL kinase inhibitor imatinib mesylate induces complete cytogenetic responses (CCR) in a high proportion of chronic myelogenous leukemia (CML) patients.
Introduction
Chronic myeloid leukemia is a lethal hematopoietic stem cell malignancy characterized by the t (9; 22) chromosomal translocation resulting in the formation of the BCR-ABL fusion gene. 1, 2 The BCR-ABL gene is known to be essential to the pathogenesis of CML.
The BCR-ABL gene product demonstrates constitutively activated tyrosine kinase activity. 3 CML invariably progresses from an initial chronic phase (CP) to an accelerated phase (AP) and terminal blast crisis (BC).
Imatinib mesylate, an inhibitor of the BCR-ABL tyrosine kinase, has proven highly effective in the treatment of CML. [4] [5] [6] Imatinib induces complete cytogenetic responses (CCR) in approximately 80% of newly diagnosed chronic phase patients and has emerged as the first-line therapy for CML. 7 Imatinib is effective in inducing hematological and cytogenetic responses in patients in accelerated phase and blast crisis. [8] [9] [10] Although relapses are infrequent in chronic phase patients, the long-term durability of response remains unclear because of limited follow up. The results of sensitive RT-PCR analyses indicate that BCR-ABL transcripts are markedly reduced in imatinib-treated patients but that complete molecular remissions are rare. 11 We and others have shown that exposure to imatinib may not completely eliminate leukemic progenitors, and that BCR-ABL+ progenitors can be detected in patients in CCR on imatinib treatment. [12] [13] [14] [15] [16] The mechanisms underlying incomplete elimination of malignant progenitors in imatinibtreated patients are not clear. There is evidence that quiescent primitive CML progenitors may be resistant to apoptosis following imatinib exposure. 13, 14 Primitive progenitors may be resistant to imatinib through mechanisms such as increased drug efflux activity. 17 For personal use only. on . by guest www.bloodjournal.org From However, another possibility is that mechanisms known to cause secondary resistance to imatinib could be active in subsets of CML progenitors, allowing their persistence in the setting of overall responsiveness to the drug.
The most common mechanisms of acquired resistance to imatinib are BCR-ABL amplification at the genomic or transcript level and point mutations in the kinase domain. [18] [19] [20] Several BCR-ABL kinase domain mutations have been reported. The Y253, E255, T315, and M351 mutations account for approximately 60% of those detected at the time of relapse. Structural data suggest that these mutations may interfere with imatinib binding to the ABL kinase domain by interrupting critical contact points or by inducing a conformation to which drug binding is reduced. [20] [21] [22] Some mutants, such as T315I and E255K are insensitive to imatinib at clinically achievable doses, whereas others such as M351T or Y253F retain intermediate levels of sensitivity to imatinib. 23 The probability of finding a mutation increases with disease duration and with advanced disease stage. 24 Mutations may be detected even prior to initiation of treatment with imatinib in some patients, and are hypothesized to result from an inherent genetic instability in BCR-ABL transformed cells. 20 Detection of a mutation is associated with an increased risk of relapse, with mutations in ATP-binding loop of the BCR-ABL kinase in particular conferring a poor prognosis. 20, 24 These studies support the hypothesis that expansion of mutant clones under selective pressure of imatinib leads to clinical relapse. 20 Patients with CCR on imatinib but with minimal residual disease represent the largest group of CML patients at the present time. In this study we investigated whether mutations in the BCR-ABL kinase domain were present in CD34+ progenitor cells from 
Materials and Methods

Patients and Samples
Bone marrow (BM) or peripheral blood stem cell (PBSC) samples were obtained using guidelines approved by the Institutional Review Board of the City of Hope National Medical Center. Inclusion criteria included a diagnosis of CML in CP or AP, CCR after imatinib treatment and informed consent to donate additional marrow or blood samples for the research studies. Samples were selected for analysis based on availability of adequate material for the planned studies. CCR was defined as the complete absence of t Bone marrow mononuclear cells (MNC) were isolated by Ficoll-Hypaque (Sigma Diagnostics, St. Louis, MO) density gradient separation (specific gravity 1.077) for 30 minutes at 400g. CD34+ cell enriched populations were selected from BM MNC or PBSC using immunomagnetic column separation (Miltenyi Biotech Inc., Auburn, CA).
Mutation analysis
Analysis of mutations was performed using a method modified from Shah et al. 20 RNA was extracted using Triazol reagent (Life Technologies, Long Island, NY). The BCR-ABL kinase domain was amplified using a two-step RT-PCR procedure. cDNA was generated by reverse transcription followed by a first-step PCR reaction to isolate a 1.3-kb cDNA fragment, which included the BCR-ABL junction and the ABL kinase domain. The
For personal use only. on . by guest www.bloodjournal.org From primers used for reverse transcription and first-step PCR were CM10 (5'-GAAGCTTCTCCCTGACATCCGT-3') and 3' ABL (5'-GCCAGGCTCTCGGGTGCAGTCC-3'). A second-step PCR reaction was performed to isolate the ABL kinase domain using the primers 5' ABL (5'-GCGCAACAAGCCCACTGTCTATGG-3') and 3' ABL (as above). The resulting 0.6-kb fragment was subcloned into the PCRII-TOPO vector (Invitrogen). Ten to twenty colonies per sample were sequenced in both directions. A mutation was considered to be present in a sample if it was detected on both strands of two or more independent clones.
The sensitivity and reproducibility of the mutation detection assay was validated using known dilutions of a BCR/ABL mutant (L248V) mixed with wild type BCR/ABL plasmids. Mutant BCR/ABL genes were reliably detected when they constituted 25% of the mixture, but detection was less consistent when mutant BCR/ABL constituted 12.5% of the mixture (mutants detected in 2 of 4 experiments) indicating proximity to the limits of sensitivity of the assay. The assay was specific since no abnormal clones other than the mutant clone being tested were detected in these experiments. 
Site-directed mutagenesis and generation of mutant alleles
Retroviral transduction
Infectious virus particles were produced by transient transfection of 293 cells with the retroviral vector plasmid and the pCL-ampho plasmid (kindly provided by Dr. Martin Haas, University of California San Diego, San Diego, CA) as previously described.
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Statistical analysis
Differences in characteristics between groups were analyzed using students' t-tests.
Relapse free survival curves were calculated by the method of Kaplan and Meier. Relapse-free survival was defined as survival without morphologic or cytogenetic evidence of recurrent leukemia in either the marrow or blood.
Results
Thirteen patients with CML (12 in CP and 1 in AP prior to starting imatinib treatment) who achieved CCR on imatinib treatment were studied. Patient characteristics are shown in Table 1 . The median time from diagnosis to study was 15 months (range 6-60 months), from diagnosis to initiation of imatinib was nine months (range 1-57 months), and from initiation of imatinib treatment to study was six months (range 3-25 months). Six patients received prior treatment with interferon-. BM cells were studied from 11 patients, whereas G-CSF mobilized PBSC were studied from two patients. CD34+ cells were selected for study in all patients save one, in whom BMMNC were studied. All patients were treated with standard doses (400mg/day) of imatinib. BCR-ABL transcripts were detected using RT-PCR techniques in MNC from all patients.
As shown in Table 1 , point mutations resulting in amino acid changes in the BCR-ABL kinase domain were identified in 5 of the 13 patients studied. Seven different mutations were detected. The L248V and D276G mutations have been previously reported. 24, 28 The other mutations, to the best of our knowledge, have not been previously described in imatinib-treated CML patients. However, three mutations (G321E, E352G, and E373G) are at locations that have been previously identified to be associated with imatinib resistance using a mutational screen. 29 The frequency of mutant subclones varied between samples, and multiple clonal abnormalities were observed in some samples. We did not observe significant differences in patient age, prior therapy with interferon, time from diagnosis to study, time from diagnosis to imatinib treatment and duration of imatinib treatment. No significant difference in levels of BCR-ABL mRNA levels as determined by Q-PCR was seen between MNC from patients with or without mutations.
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Since most of the observed mutations were novel, sensitivity to inhibition by imatinib was tested. The M237I, L248V, D276G, G321E, E352G, Y353G and E373G mutations were introduced into wild-type BCR-ABL genes by site-directed mutagenesis followed by No evidence of cytogenetic or hematological relapse was observed in the eight patients in whom kinase mutations were not detected, with a median follow up of 27 months (range 12-34 months) ( Table 1) . Detection of a kinase domain mutation was associated with a trend towards increased risk of relapse (p=0.058). Of five patients in whom kinase domain mutations were detected, two subsequently relapsed (Table 1) . One patient who relapsed (No. 4) was detected to have the L248V mutation when studied in CCR 24 months after initiation of imatinib. This mutation, located in the ATP-binding loop (Ploop) of the ABL kinase domain, is associated with a relatively high degree of imatinib
resistance. This patient developed cytogenetic evidence of relapse 9 months from the time this sample was collected, and subsequently developed hematological relapse. The L248V mutation was observed at high frequency in blood samples collected following relapse. The second patient who relapsed (No. 3) was detected to have two mutant clones (E352G, Y353H) when studied in CCR four months after initiation of imatinib. This patient relapsed in blast crisis two months after this sample was obtained. A new mutation (D276G) was seen at the time of relapse, but the two mutations originally seen were no longer detected. As expected increased BCR-ABL mRNA levels on Q-PCR analysis were observed in these two patients. Three other patients in whom kinase domain mutations were detected continued to be in CCR with follow up of 21, 27 and 30 months. Follow up samples were available for analysis from two patients. In one patient (No. 1) the M237I mutation detected at the first assessment, was detected once again on re-evaluation seven months later. Three additional mutations (E352G, V304A, M351T) that had not been previously detected were also seen. Q-PCR analysis showed increased BCR-ABL levels in this sample. In the other patient (No. 2) three mutations originally detected were not seen on re-evaluation four months later, but two new mutations (E352G, T389A) were detected. Q-PCR analysis did not reveal a consistent rise in BCR-ABL levels in follow-up samples from this patient. For patients without BCR-ABL mutations, Q-PCR analysis revealed increased BCR-ABL levels in follow up samples from five patients, confirmed in two or more follow-up samples in three patients, and unchanged or reduced levels in three patients. Patients with rising levels of BCR/ABL on Q-PCR were analyzed for kinase mutations. Mutations were detected in follow up samples from four of the five patients with rising BCR/ABL levels ( 
Discussion
Although the majority of CML patients treated with imatinib achieve CCR, complete molecular remissions are rare. 11 The mechanisms underlying resistance of a subset of Two patients in whom mutations were initially detected subsequently relapsed. In one patient the L248V P-loop mutation was present in CD34+ cells when the patient was evaluated in CCR and was also detected at high frequency in peripheral blood cells at the time of clinical relapse, suggesting that relapse was likely related to selective outgrowth of cells bearing this mutation. This mutation resulted in significant resistance to kinase inhibition by imatinib. The second patient who relapsed rapidly evolved to blast crisis. The originally observed clone was not seen at relapse, but two new mutations were seen.
It is possible that underlying genetic instability could have contributed to rapid evolution to blast crisis in this patient. The eight patients in whom mutations were not detected have stayed in continued CCR. However some of these patients have also shown evidence of rising BCR-ABL levels on Q-PCR analysis. Although rising BCR-ABL levels are associated with increased risk of relapse in CML patients post-allogeneic hematopoietic cell transplantation, the clinical significance of increasing BCR-ABL levels in imatinib-treated patients in CCR has not been definitively proven at this time. 26 It appears logical that patients with rising burden of leukemic cells may be at increased risk of relapse. Significantly, kinase mutations were detected in follow up samples from four of five patients with rising Q-PCR levels, in whom mutations were not originally detected. Consistent with these results, Branford et al. have recently reported that rising BCR-ABL mRNA levels in imatinib treated patients, including patients in CCR, was associated with a high incidence of kinase mutations. 30 Since our study included a relatively small number of patients, one cannot exclude the possibility that the population studied may be skewed towards a more high-risk population of CML patients who achieve CCR. Larger, population based studies with extended follow up will be required to estimate the true incidence of kinase mutations in this patient population, to confirm the association between mutations and clinical relapse, and determine whether screening for mutations may be helpful for risk stratification and prognostication in patients responsive to imatinib treatment.
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present at low frequency, close to the limits of sensitivity of the assay, may not be consistently detected.
Since most of the mutations detected here resulted in reduced in vitro sensitivity to imatinib, it is likely that the presence of such mutations contributed at least in part to disease persistence in these patients. It is also possible that the presence of mutations could reflect an underlying genetic instability, and that patients bearing mutations may be at increased risk for acquiring additional genetic abnormalities contributing to disease persistence or progression. However, it is likely that additional factors besides kinase domain mutations may also contribute to the persistence of subsets of malignant progenitors in imatinib-responsive CML patients. First, kinase domain mutations could not be detected in several patients. Second, even for patients in whom mutations were detected, kinase mutations were not seen in a large proportion of subclones. However, we cannot exclude the possibility of mutations outside the kinase domain that might affect imatinib sensitivity, as was reported in an in vitro screen. 29 Other potential mechanisms that could contribute to the persistence of primitive malignant progenitors include insensitivity of quiescent primitive progenitors to imatinib-induced apoptosis, 13, 14 transmission of survival or proliferation signals in response to microenvironmental stimuli, 31 and acquisition of genetic abnormalities in genes other than BCR/ABL. Eight patients were common to the two studies. Of these five had mutations detected in the present study, and all had BCR/ABL+ cells detected on FISH in the previous study. BCR/ABL+ CD34+ cells were detected by FISH in 2 of the 3 patients in whom mutations were not detected in this study. 2 Mutation analysis on follow-up samples was performed using RNA extracted from CD34+ cells for patients 1,2 and 3 and from MNC for patients 4, 6,7,10, 11 and 12. 3 These patients had rising BCR/ABL mRNA levels on Q-PCR analysis 4 The V304G and M351T mutations were detected simultaneously in 3 clones 
